Asset
NOMACOPAN
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03427060 | phase2 | completed | 2018-05-14 | 2018-11-15 | AKARI Therapeutics | Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms |
| NCT02591862 | phase2 | completed | 2016-02-01 | 2018-03-20 | AKARI Therapeutics | Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) |
| NCT04784455 | phase3 | terminated | 2021-02-01 | 2024-05-15 | AKARI Therapeutics | Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy |
| NCT05061771 | phase3 | withdrawn | 2022-05-06 | 2022-08-01 | AKARI Therapeutics | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) |
FDA applications (0)
This company has no applications containing this asset.